PDGFRA and neoplasm: Patients with a significant (>1+) increase in PDGFRα expression after treatment with BRAF-I +/- MEK-I had less tumor regression (Figure 3B) and shorter time to disease progression (Figure 3C) (P=0.07) when compared to patients who had no change or a small change in PDGFRα expression (≤1+).